Huge news in APOL1 nephropathy - ten tweets to fill you in here:
This week, we will discuss the use of LLMs for the diagnosis of complex nephrology cases. Can AI help nephrologists nail the correct diagnosis?
MERCURI-2 reports that dapagliflozin cuts postoperative AKI after cardiac surgery, but the headline result is mostly a urine-output story, not a creatinine one. That matters: urine output after surgery is easily swayed by anesthesia, fluid shifts, vasopressors, and a diuretic drug in the mix. Until dapagliflozin shows it protects kidney function, not just urine output.
This week, we will discuss SODaBIC trial: with ICU acidosis driven by multiple overlapping mechanisms, is bicarbonate infusion supported by robust evidence, or does it persist mainly out of habit rather than physiology?
FIND-CKD extends finerenone beyond diabetic kidney disease, showing slower eGFR decline and sustained albuminuria reduction in non-diabetic CKD. While the benefits are modest and cardiovascular effects remain uncertain, the trial opens the door to broader use of nsMRAs and raises important questions about combination therapy with SGLT2 inhibitors.
Huge news in APOL1 nephropathy - ten tweets to fill you in here:
Welcome to #TenTweetNephJC
— Nephrology Journal Club (@NephJC) May 12, 2023
✳️10 tweets #NephJC catch-up ✳️
On 4/25-26, we discussed the phase II study examining inaxaplin treatment, a small molecule inhibitor, in APOL1 nephropathy. This is the first drug specifically targeting this disease.
Join us here for the recap! pic.twitter.com/LApAHkYn10